INTRODUCTION Globally, the total number of people with depression exceeds 300 million, and the incidence rate is 70 % greater in women. The perimenopause is considered to be a time of increased risk for the development of depressive symptoms and major depressive episodes. AIM The aim of this position statement is to provide a comprehensive model of care for the management of depressive symptoms in perimenopausal and early menopausal women, including diagnosis, treatment and follow-up. The model integrates the care provided by all those involved in the management of mild or moderate depression in midlife women. MATERIALS AND METHODS Literature review and consensus of expert opinion. SUMMARY RECOMMENDATIONS Awareness of depressive symptoms, early detection, standardized diagnostic procedures, personalized treatment and a suitable follow-up schedule need to be integrated into healthcare systems worldwide. Recommended treatment comprises antidepressants, psychosocial therapies and lifestyle changes. Alternative and complementary therapies, although widely used, may help with depression, but a stronger evidence base is needed. Although not approved for this indication, menopausal hormone therapy may improve depressive symptoms in peri- but not in postmenopausal women, especially in those with vasomotor symptoms.

中文翻译：

---

围绝经期和绝经后妇女抑郁症状的管理：EMAS 立场声明

引言 在全球范围内，抑郁症患者总数超过 3 亿，女性的发病率高出 70%。围绝经期被认为是抑郁症状和重度抑郁发作风险增加的时期。目的 本立场声明的目的是为围绝经期和早期绝经期妇女的抑郁症状管理提供一个全面的护理模式，包括诊断、治疗和随访。该模型整合了所有参与管理中年妇女轻度或中度抑郁症的人员提供的护理。材料与方法 文献回顾和专家意见共识。总结建议 对抑郁症状的认识、早期发现、标准化诊断程序、个性化治疗和合适的随访计划需要整合到全球医疗保健系统中。推荐的治疗方法包括抗抑郁药、心理社会疗法和生活方式的改变。替代疗法和补充疗法虽然被广泛使用，但可能有助于治疗抑郁症，但需要更有力的证据基础。虽然没有批准用于该适应症，但绝经期激素治疗可能会改善围绝经期妇女的抑郁症状，但不能改善绝经后妇女的抑郁症状，尤其是那些有血管舒缩症状的妇女。